Skip to Content

Zaltrap Approval History

  • FDA approved: Yes (First approved August 3rd, 2012)
  • Brand name: Zaltrap
  • Generic name: ziv-aflibercept
  • Dosage form: Injection
  • Company: Sanofi and Regeneron Pharmaceuticals, Inc.
  • Treatment for: Colorectal Cancer

Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.

Development History and FDA Approval Process for Zaltrap

Aug  3, 2012Approval FDA Approves Zaltrap for Metastatic Colorectal Cancer
Apr  5, 2012Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap (aflibercept)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.